Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow EW
Edwards Lifesciences Corporation (EW) EV/Sales
As of 16 October 2026, Edwards Lifesciences Corporation (EW) trades at a EV/Sales of 7.2×. Over the past ten years it has ranged from 5.3× (May 2015) to 15.9× (December 2021); the current reading is higher than 21% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.7× | 1.23% |
| FY2024 | 7.6× | (15.89%) |
| FY2023 | 9.1× | (11.95%) |
| FY2022 | 10.3× | (33.07%) |
| FY2021 | 15.4× | 19.21% |
| FY2020 | 12.9× | 16.24% |
| FY2019 | 11.1× | 28.00% |
| FY2018 | 8.7× | 28.24% |
| FY2017 | 6.8× | 0.72% |
| FY2016 | 6.7× | 2.12% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.5× | 8.21% |
| Mar 2026 | 7.0× | (9.74%) |
| Dec 2025 | 7.7× | 6.02% |
| Sep 2025 | 7.3× | (3.86%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PHG Koninklijke Philips N.V. compare | 1.4× |
| GEHC GE HealthCare Technologies Inc. compare | 1.9× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.0× |
| BSX Boston Scientific Corporation compare | 3.7× |
| MDT Medtronic PLC compare | 3.7× |
| STE STERIS plc compare | 3.8× |
| SYK Stryker Corporation compare | 4.8× |
| DXCM DexCom, Inc. compare | 6.6× |
| EW Edwards Lifesciences Corporation | 7.2× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on EW
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement